Capital Fund Management (CFM)’s Sarepta Therapeutics SRPT Stock Holding History

Capital Fund Management (CFM)’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$411K	Sell	18,900 -93,800	-83%	-$1.82M	﹤0.01%	1912
2025 Q4	$2.43M	Sell	112,700 -23,600	-17%	-$497K	0.01%	1609
2025 Q3	$2.63M	Buy	136,300 +91,700	+206%	+$1.63M	0.01%	1640
2025 Q2	$763K	Buy	+44,600	New	+$1.9M	﹤0.01%	2090
2019 Q1	–	Sell	-13,900	Closed	-$1.52M	–	2070
2018 Q4	$1.52M	Sell	13,900 -18,700	-57%	-$2.34M	0.01%	950
2018 Q3	$5.26M	Buy	32,600 +24,600	+308%	+$3.36M	0.03%	746
2018 Q2	$1.06M	Buy	+8,000	New	+$754K	0.01%	1313
2013 Q4	–	Sell	-9,100	Closed	-$430K	–	1832
2013 Q3	$430K	Buy	+9,100	New	+$350K	0.01%	1219

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Fund Management (CFM)'s SRPT Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its Sarepta Therapeutics (SRPT) stake by 5.4% in Q1 2026, selling an estimated $506K and leaving 459,322 shares worth $9.99M. The position accounts for 0.05% of the portfolio, ranked #553.

Capital Fund Management (CFM) first reported a position in SRPT in Q3 2013 and has held it in 27 quarters since. The position peaked at $25.5M in Q3 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Capital Fund Management (CFM) held 459,322 shares of Sarepta Therapeutics worth $9.99M as of Q1 2026.
Capital Fund Management (CFM) sold 26,131 Sarepta Therapeutics shares in Q1 2026, an estimated $506K.
Sarepta Therapeutics made up 0.05% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #553 holding.
Capital Fund Management (CFM) first reported a position in Sarepta Therapeutics in Q3 2013 and has held it in 27 quarters since.
Capital Fund Management (CFM)'s Sarepta Therapeutics position peaked at $25.5M in Q3 2024.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.